Janux Therapeutics, Inc. (JANX)

NASDAQ: JANX · IEX Real-Time Price · USD
10.35
-0.38 (-3.54%)
May 20, 2022 4:00 PM EDT - Market closed

Company Description

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer.

The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.

Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells.

In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Janux Therapeutics, Inc.
CountryUnited States
Founded2017
IPO DateJun 11, 2021
IndustryBiotechnology
SectorHealth Care
Employees41

Contact Details

Address:
11099 North Torrey Pines Road
La Jolla, CA 92037
United States
Phone858 750 4700

Stock Details

Ticker SymbolJANX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$17.00
CIK Code1817713

Key Executives

NamePosition
Dr. David Alan Campbell Ph.D.President, Chief Executive Officer and Director
Dr. Shahram Salek-Ardakani Ph.D.Chief Scientific Officer
Dr. Wayne Godfrey M.D.Chief Medical Officer
Tighe M. Reardon C.F.A., CPA, CPAActing Chief Financial Officer
Tommy Diraimondo Ph.D.Director of Research
Andy Hollman MeyerChief Business Officer
Charles M. WinterSenior Vice President of Chemistry, Manufacturing and Controls
Byron Robinson J.D., Ph.D.Chief Strategy Officer

Latest SEC Filings

DateTypeTitle
May 10, 202210-QQuarterly report [Sections 13 or 15(d)]
May 10, 20228-KCurrent report
May 2, 20228-KCurrent report
Apr 29, 2022DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2022DEF 14AOther definitive proxy statements
Mar 18, 2022S-8Securities to be offered to employees in employee benefit plans
Mar 18, 202210-KAnnual report [Section 13 and 15(d), not S-K Item 405]
Mar 18, 20228-KCurrent report
Mar 3, 20224Statement of changes in beneficial ownership of securities
Mar 3, 20223Initial statement of beneficial ownership of securities
View All SEC Filings